Shire announces availability of MYDAYIS(TM) for ADHD treatment in the U.S.

|About: Shire PLC (SHPG)|By:, SA News Editor

Shire plc (NASDAQ:SHPG) announces that MYDAYIS(NYSE:TM) (mixed salts of a single-entity amphetamine product), a once-daily, extended-release treatment comprised of three types of drug-releasing beads, is now available by prescription in the U.S.

The FDA approved Mydayis for patients 13 years and older with Attention Deficit Hyperactivity Disorder (ADHD).

Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-dose, compared to placebo, in total score on a skill-adjusted math test that measures attention in ADHD.